Enhanced immunogenicity of HPV16E7 accompanied by Gp96 as an adjuvant in two vaccination strategies

2008/04/19 by Azam Bolhassani, Farnaz Zahedifard, Mohammad Taghikhani +1 · 14 citations
Medicine · Immunology and Microbiology · Biochemistry, Genetics and Molecular Biology · #Hepatitis B Virus Studies #Immunotherapy and Immune Responses #Virus-based gene therapy research

paper · doi:10.1016/j.vaccine.2008.03.082

Cited by

• Development of HPV nanovaccine candidate based on IL-15-E7 fusion protein encapsulated in silk-fibroin nanoparticles
• Perspectives for preventive and therapeutic HPV vaccines. [europepmc]
• Immunotherapy for cervical cancer: Research status and clinical potential. [europepmc]
• Co-administration of GP96 and Her2/neu DNA vaccine in a Her2 breast cancer model. [europepmc]
• Mini-chaperones: potential immuno-stimulators in vaccine design. [europepmc]
• Expression, purification and characterization of a recombinant fusion protein based on the human papillomavirus-16 E7 antigen. [europepmc]
• Recombinant Nonstructural 3 Protein, rNS3, of Hepatitis C Virus Along With Recombinant GP96 Induce IL-12, TNFα and α5integrin Expression in Antigen Presenting Cells. [europepmc]
• Evaluation of Cell Penetrating Peptide Delivery System on HPV16E7 Expression in Three Types of Cell Line. [europepmc]
• LncRNA and mRNA profiling during activation of tilapia macrophages by HSP70 and Streptococcus agalactiae antigen. [europepmc]
• Human Neutrophil Peptide 1 as immunotherapeutic agent against Leishmania infected BALB/c mice. [europepmc]
• In vivo delivery of a multiepitope peptide and Nef protein using novel cell-penetrating peptides for development of HIV-1 vaccine candidate. [europepmc]
• Heat Shock Proteins 90 kDa: Immunomodulators and Adjuvants in Vaccine Design Against Infectious Diseases. [europepmc]
• HCV Core/NS3 Protein Immunization with "N-Terminal Heat Shock gp96 Protein (rNT (gp96))" Induced Strong and Sustained Th1-Type Cytokines in Immunized Mice. [europepmc]
• Enhancement of potent immune responses to HPV16 E7 antigen by using different vaccine modalities [europepmc]